Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo In Macular Edema Due To Branch And Central Retinal Vein Occlusion
Roche's Genentech Announces New 72-Week Data From BALATON And COMINO, Evaluating Vabysmo In Macular Edema Due To Branch And Central Retinal Vein Occlusion
罗氏基因泰克公布了来自BALATON和COMINO的72周新数据，评估了Vabysmo在分支和视网膜中央静脉阻塞导致的黄斑水肿中的作用
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –
Vabysmo 持续严重干燥视网膜液体，通常与视力失真或模糊有关 —
– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –
— 接受Vabysmo治疗的人中有多达60％能够将治疗间隔延长至相隔三到四个月 —
– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024 –
— 两项全球III期RVO研究的详细结果将在2024年血管生成、渗出和变性上公布
– Vabysmo is approved in the U.S. for RVO, and in more than 90 countries around the world for people living with wet AMD and DME –
— Vabysmo在美国获准使用RVO，全球90多个国家批准用于湿性AMD和DME患者 —